These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

559 related items for PubMed ID: 26825070

  • 1. Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins.
    Scacchi M, Danesi L, Cattaneo A, Sciortino G, Radin R, Ambrogio AG, Vitale G, D'Angelo E, Mirra N, Zanaboni L, Arvigo M, Boschetti M, Ferone D, Marzullo P, Baldini M, Cassinerio E, Cappellini MD, Persani L, Cavagnini F.
    Endocrine; 2016 Aug; 53(2):551-7. PubMed ID: 26825070
    [Abstract] [Full Text] [Related]

  • 2. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
    Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Corneli G, Ghigo E, Lombardi G.
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
    [Abstract] [Full Text] [Related]

  • 3. Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites.
    Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C, D'Angelo E, Mirra N, Carnelli V, Zanaboni L, Tampieri B, Cappellini MD, Cavagnini F.
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):202-7. PubMed ID: 18221395
    [Abstract] [Full Text] [Related]

  • 4. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender.
    Rota F, Savanelli MC, Tauchmanova L, Savastano S, Lombardi G, Colao A, Di Somma C.
    J Endocrinol Invest; 2008 Feb; 31(2):94-102. PubMed ID: 18362499
    [Abstract] [Full Text] [Related]

  • 5. Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover.
    Gürlek A, Gedik O.
    J Endocrinol Invest; 2001 Jun; 24(6):408-14. PubMed ID: 11434664
    [Abstract] [Full Text] [Related]

  • 6. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone deficiency (GHD) in adult thalassaemic patients.
    Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C, D'Angelo E, Mirra N, Carnelli V, Zanaboni L, Cappellini MD, Cavagnini F.
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):790-5. PubMed ID: 17608814
    [Abstract] [Full Text] [Related]

  • 8. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
    Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E.
    Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
    [Abstract] [Full Text] [Related]

  • 9. The association of testosterone, sex hormone-binding globulin, and insulin-like growth factor-1 with bone parameters in Korean men aged 50 years or older.
    Kim HJ, Koo HS, Kim YS, Kim MJ, Kim KM, Joo NS, Haam JH.
    J Bone Miner Metab; 2017 Nov; 35(6):659-665. PubMed ID: 27873076
    [Abstract] [Full Text] [Related]

  • 10. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of bone mineral density of the lumbar spine in patients with beta-thalassemia major with dual-energy x-ray absorptiometry and quantitative computed tomography: a comparison study.
    Angelopoulos NG, Katounda E, Rombopoulos G, Goula A, Kaltzidou V, Kaltsas D, Ioannis P, Tolis G.
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):73-8. PubMed ID: 16462577
    [Abstract] [Full Text] [Related]

  • 12. The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60.
    Kim JG, Shin CS, Choi YM, Moon SY, Kim SY, Lee JY.
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):301-7. PubMed ID: 10469009
    [Abstract] [Full Text] [Related]

  • 13. Analysis of bone mineral density and turnover in patients with cystic fibrosis: associations between the IGF system and inflammatory cytokines.
    Street ME, Spaggiari C, Ziveri MA, Volta C, Federico G, Baroncelli GI, Bernasconi S, Saggese G.
    Horm Res; 2006 Sep; 66(4):162-8. PubMed ID: 16804317
    [Abstract] [Full Text] [Related]

  • 14. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM, Ostertag A, Schulten K, Schulz W, Jehle DR, Stracke S, Fiedler R, Deuber HJ, Keller F, Boehm BO, Baylink DJ, Mohan S.
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [Abstract] [Full Text] [Related]

  • 15. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 16. Impact of the growth hormone replacement on bone status in growth hormone deficient adults.
    Kužma M, Kužmová Z, Zelinková Z, Killinger Z, Vaňuga P, Lazurová I, Tomková S, Payer J.
    Growth Horm IGF Res; 2014 Feb; 24(1):22-8. PubMed ID: 24382377
    [Abstract] [Full Text] [Related]

  • 17. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
    Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A.
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
    [Abstract] [Full Text] [Related]

  • 18. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis.
    Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ.
    J Bone Miner Res; 1999 Dec; 14(12):2150-8. PubMed ID: 10620075
    [Abstract] [Full Text] [Related]

  • 19. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ, Hamdy NA, Frölich M, Roelfsema F.
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
    [Abstract] [Full Text] [Related]

  • 20. Relationship among insulinlike growth factor I concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women: a population-based study.
    Nabipour I, Larijani B, Beigi S, Jafari SM, Amiri M, Assadi M, Pazoki R, Amiri Z, Sanjdideh Z.
    Menopause; 2008 Jun; 15(5):934-9. PubMed ID: 18451743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.